Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

Meletios A Dimopoulos,Dominik Dytfeld,Sebastian Grosicki,Philippe Moreau,Naoki Takezako,Mitsuo Hori,Xavier Leleu,Richard LeBlanc,Kenshi Suzuki,Marc S Raab,Paul G Richardson,Mihaela Popa McKiver,Ying-Ming Jou,David Yao,Prianka Das,Jesús San-Miguel

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 18|浏览42

暂无评分

摘要

EPd demonstrated a statistically significant improvement in OS versus Pd in patients with RRMM previously treated with lenalidomide and a PI who had disease refractory to last therapy. In this setting, ELOQUENT-3 is the first randomized study of a triplet regimen incorporating a monoclonal antibody and Pd to improve both PFS and OS significantly.

查看译文

关键词

relapsed/refractory multiple myeloma,multiple myeloma,final overall survival analysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要